Articles tagged with Antisense Rna
Researchers suggest treatment could start during pregnancy to prevent brain damage and reduce neurological harm. A new RNA-based therapy reduces abnormal electrical currents in patient-derived excitatory neurons.
Researchers found that an ASO strategy boosts expression of the closely related HNRNPH1 protein, reducing symptoms of HNRNPH2-related neurodevelopmental disorder. The study provides vital mechanistic data to support advancement of this promising therapy.
Researchers have discovered a complex regulatory circuit involving SRSF1, AURKA, and MYC that promotes aggressive pancreatic cancer progression. The circuit, which involves alternative splicing, can be targeted with an antisense oligonucleotide to reduce tumor cells' viability and trigger apoptosis.
Researchers developed an RNA-based therapeutic strategy targeting mutant KRAS genes, stimulating the immune system to attack tumours. The treatment, combining antisense oligonucleotides and immunomodulatory RNA, effectively killed cancer cells in laboratory studies, reducing tumour burden and extending survival.
Scientists have discovered that repeat RNAs aggregate inside droplets but can be disassembled with an engineered piece of RNA. The study sheds new light on how these clusters form within biomolecular condensates and presents a potential therapeutic application.
Researchers discovered that slowing down intracellular transport of RNA-based drugs increases their effectiveness in treating genetic diseases. The study identified key genes involved in endosomal transport and found that selectively switching off a specific gene can prolong ASO residence time, boosting therapeutic efficacy.
Researchers developed nanomachines that can efficiently deliver antisense oligonucleotides to sentinel lymph nodes, reducing TGF-β1 levels and reactivating depleted CD8-positive T cells. This enhances cancer treatment outcomes for advanced breast cancers with no effective treatments.
Researchers at Chung-Ang University have identified a crucial role for specific tRNA fragments in cancer progression, revealing their ability to regulate gene expression and influence tumor growth. The study suggests that these fragments could serve as biomarkers for early-stage cancer detection and targets for therapeutic interventions.
Researchers successfully delivered anti-cancer ASO molecules to lung tumor sites using human red blood cells, demonstrating potent anti-cancer effects against NSCLC. The approach utilizes EGFR-targeting moieties to home in on cancerous cells, offering a potentially powerful treatment modality for personalized cancer medicine.
Researchers from Tokyo Medical and Dental University demonstrate a proof of concept for antisense nucleic acid therapy to prevent the spread of α-synuclein pathologies in synucleinopathies. The treatment, involving antisense oligonucleotides, effectively reduces Lewy pathology-like neuronal inclusion by over 90%.
A research team from Göttingen University has discovered that antisense RNA (asRNA) plays a crucial role in cell transport, allowing cells to accelerate gene expression and produce proteins quickly in response to environmental stress or harm. This new understanding sheds light on the function of asRNAs and their potential link to disea...
Researchers from Osaka University have discovered a way to deliver antisense oligonucleotides to their targets inside cancer cells by opening specific calcium permeable channels. The new compound, L687, promotes efficient uptake of ASO into cancer cells, suppressing target gene activity and enhancing ASO efficacy.
Researchers at Johns Hopkins Medicine have developed a novel approach to target group 3 medulloblastoma tumors in mice, reducing tumor growth by 40-50% and extending survival by up to 84 days. The therapy uses antisense oligonucleotides to block lnc-HLX-2-7 from binding to the HLX promoter region.
Researchers at Martin-Luther-Universität Halle-Wittenberg developed novel RNA- or DNA-based substances that reliably fight off viral infections in plants. The new approach uses antisense oligonucleotides to target specific viral RNA molecules, achieving an impressive up to 90% success rate against a common virus.
A novel antisense therapy has restored fragile X protein production in human cell samples, revealing aberrant alternative splicing of messenger RNA as a key factor in fragile X syndrome. This finding offers real hope for developing new treatments and improving the lives of individuals affected by the condition.
A new research centre will focus on developing new types of RNA medicine for treating metabolic diseases. The centre, led by Professor Jørgen Kjems at Aarhus University, aims to create targeted treatments for conditions like diabetes and atherosclerosis.
Researchers at Tokyo Medical and Dental University have found that a specific lipid, alpha-tocopherol, increases the uptake of antisense oligonucleotides in the stroke-lesioned brain. This delivery method has potential for targeted protein expression after a stroke.
Scientists have discovered a new layer of regulation in plant-microbe interactions using peanut studies. An antisense long-noncoding RNA, DONE40, was found to bind to a protein involved in epigenetic control, suggesting a conserved function across plants and animals.
Scientists have discovered that an antisense RNA can induce the formation of fusion genes in mammalian cells, which may lead to new cancer therapies and biomarkers. The 'cart before the horse' hypothesis is challenged by this finding, revealing a non-coding RNA's role in gene recombination.
Scientists have discovered a novel approach to treating ALS by targeting toxic RNA, which aggregates into foci in the brain. The new therapy uses antisense oligonucleotides to selectively degrade the toxic RNA without affecting normal RNA production.
A study published in Nature has shown that non-coding antisense RNA can stimulate protein production by acting as a 'lock' for coding RNA, enabling the action of a stimulatory sequence to promote protein synthesis.
Researchers have discovered a novel function of non-coding antisense RNA, which enhances the translation of protein coding mRNAs by increasing association with ribosomes. This finding has significant implications for therapeutic applications and challenges current understanding of non-coding RNAs.
Researchers have reversed symptoms of myotonic muscular dystrophy in mice by targeting and eliminating toxic RNA in muscle cells. The treatment approach has shown significant promise, reducing symptoms by up to one year in a mouse model.
Myotonic dystrophy is caused by a mutation that causes toxic RNA to accumulate in cells. Antisense oligonucleotides have been shown to be effective in cell culture and mice by degrading the toxic RNA. The treatment will need to be refined for systemic delivery to patients with myotonic dystrophy.
Researchers at UNC may have found a way to awaken the dormant allele of Ube3a, leading to potential treatments for Angelman syndrome. The team used FDA-approved drugs like irinotecan and topotecan to 'awaken' the paternal allele, resulting in functional protein expression.
Researchers at Karolinska Institutet identified a new gene, Wrap53, that regulates p53 activity. The study reveals that damage to Wrap53 can indirectly cause cancer, making it a potential target for future therapies.
University of Delaware researchers have discovered a new type of molecule called natural antisense microRNAs (nat-miRNAs) that can turn off genes in rice, which is the primary source of food for half the world's population. These novel molecules may help scientists locate similar gene regulators in other organisms, including humans.
Researchers at CSHL have successfully corrected an mRNA splicing defect in SMA patients, using RNA splicing antisense technology. The therapy holds promise for treating the genetic disease, which causes progressive muscle weakness and respiratory failure.
Researchers found that antisense RNA molecules protect sex cells from self-destructing by blocking sense RNA production. This discovery reveals a new process of gene regulation and its potential application to mammals.
Researchers found that antisense RNA regulates core timing genes in Neurospora's circadian clock, which drives the 24-hour light-dark cycle. The discovery provides an unexpected link between antisense RNA and circadian timing.
Researchers at the University of Rochester have created a remarkably short antisense compound that targets Pneumocystis carinii, an opportunistic pathogen causing pneumonia in people with weakened immune systems. The breakthrough marks a step toward designing drugs that knock out vital sections of molecules essential for the microbe's ...